RAPT Therapeutics (RAPT) EPS (Weighted Average and Diluted) (2021 - 2023)
Historic EPS (Weighted Average and Diluted) for Therapeutics (RAPT) over the last 3 years, with Q4 2023 value amounting to -$0.87.
- Therapeutics' EPS (Weighted Average and Diluted) fell 3329.56% to -$0.87 in Q4 2023 from the same period last year, while for Sep 2024 it was -$0.85, marking a year-over-year increase of 7230.94%. This contributed to the annual value of -$3.31 for FY2023, which is 2845.9% down from last year.
- Latest data reveals that Therapeutics reported EPS (Weighted Average and Diluted) of -$0.87 as of Q4 2023, which was down 3329.56% from -$0.88 recorded in Q3 2023.
- Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at -$0.61 during Q4 2021, with a 5-year trough of -$0.88 in Q3 2023.
- For the 3-year period, Therapeutics' EPS (Weighted Average and Diluted) averaged around -$0.71, with its median value being -$0.65 (2022).
- As far as peak fluctuations go, Therapeutics' EPS (Weighted Average and Diluted) skyrocketed by 158.73% in 2022, and later plummeted by 4036.09% in 2023.
- Quarter analysis of 3 years shows Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.61 in 2021, then decreased by 6.56% to -$0.65 in 2022, then plummeted by 33.3% to -$0.87 in 2023.
- Its last three reported values are -$0.87 in Q4 2023, -$0.88 for Q3 2023, and -$0.74 during Q2 2023.